Biberach
The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Search
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
The Partner's Champion - Transactions and Alliance Management
Learn how our Transactions and Alliance Management teams are building successful long-term partnerships
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
Smart Factory: Digitalizing production facilities
How our digitalized production facilities help our colleagues and patients
Careers beyond borders
Careers beyond borders
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Microbial Expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins. Due to the variety of molecular formats that can be synthesised by microbes, microbial manufacturing is characterized by a broad width of production processes.
Our Purpose
Why we exist
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Transboundary animal diseases (TADs)
Avian influenza? Bluetongue virus? FMD? Learn what are transboundary animal diseases and how they can impact us
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
Better Access to Healthcare for Indigenous Peoples
Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Raising Questions or Concerns
Supplier must report ethics and compliance concerns that might affect Boehringer Ingelheim.
On two wheels for more animal health
Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
Laura loves her diverse career
Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Physical Wellbeing
Resources and videos related to physical wellbeing whilst living with cancer.
Solidarity with Ukraine
Our company condemns the military aggression against Ukraine and is committed to helping those in need in the longer term with monetary and in kind donations
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Submit your animal health partnering opportunity
Information on how to submit your animal health innovation opportunity direct to Boehringer Ingelheim’s partnering team